Edwards Lifesciences’ (EW) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Edwards Lifesciences (NYSE:EW) in a research note released on Wednesday morning,Benzinga reports. Royal Bank of Canada currently has a $85.00 target price on the medical research company’s stock.

A number of other equities analysts also recently weighed in on the stock. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Piper Sandler lifted their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Evercore ISI lowered their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday. Finally, Barclays increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $79.71.

Edwards Lifesciences Stock Performance

NYSE EW opened at $75.83 on Wednesday. The company has a market capitalization of $44.72 billion, a price-to-earnings ratio of 10.94, a PEG ratio of 3.64 and a beta of 1.10. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The stock has a fifty day simple moving average of $72.47 and a 200 day simple moving average of $69.32. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Sell-side analysts expect that Edwards Lifesciences will post 2.56 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.29% of the stock is owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds have recently modified their holdings of the stock. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $26,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $29,000. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $30,000. Finally, Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter worth about $32,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.